Does Radioiodine Therapy in Patients with Differentiated Thyroid Cancer Increase the Frequency of Another Malignant Neoplasm?

Table 4

Clinical, epidemiological, and therapeutic characteristics of 148 patients with differentiated thyroid carcinoma who received a therapeutic dose of radioactive iodine and showed another postiodine malignancy or not.

Clinical and epidemiological data	Another postradioactive iodine malignancy		Odds ratio	IC 95%	P
	Yes; 𝑁=7; (4.7%)	No; 𝑁=141 (95.3%)
Males N (%)	4 (57.1)	21 (14.9)	0.123	0.015–1.026	0.0528
Age at thyroidectomy (years)*	61±17	44.08±14.2	1.133	1.036–1.239	0.0061
Follow-up period (months)**	75 (48; 336)	74 (9; 468)	1.013	1.000–1.026	0.0514
Accumulated dose of ^131I (mCi)**	175 (100; 300)	200 (30; 870)	0.994	0.985–1.002	0.1375
Classic nonpapilliferous histological type N (%)	3 (42.8)	59 (41.8)	2.350	0.311–17.742	0.4073

*mean ± standard deviation; **median (minimum value; maximum value).